As medical knowledge now doubles every 73 days, the challenge for cardiology clinicians has shifted from finding information to mastering precision. At the ...
Appointment marks a pivotal step in Lucid’s next phase of growth, strengthening its ability to translate complex science into real-world impact. Lucid’s US Medical Affairs division unveils new ...
First-in-class oral therapy mimics the effects of exercise with broad potential as a novel treatment for muscle-sparing weight loss ...
OPEN Health today announced the appointment of Peter Black as EVP, Global Client Partner and Transformation Lead.
OPEN Health today announced the appointment of Tim Perryman as Global Head of Operations, strengthening the company’s operational leadership as it continues to scale its global capabilities and ...
OPEN Health today announced the appointment of Cara Priest as Chief People Officer, reinforcing the company’s commitment to building a high-performing culture that supports its continued growth and ...
Sandoz has appointed Armin Metzger as President, Biosimilar Development, Manufacturing & Supply. Metzger will also become a member of the Sandoz Executive Committee (SEC), effective 1 April 2026. Most ...
BioDuro has appointed Andrew Thomas (top left) and Stevan Djuric (top right) as Scientific Advisors. Thomas was formerly ...
The antibiotics are needed to combat key drug-resistant bacteria causing severe bloodstream and urinary tract infections, ...
Odyssey Therapeutics, a clinical-stage biopharmaceutical company, has appointed H. Martin Seidel to its Scientific Advisory ...
Imfinzi (durvalumab), in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel), has received EU approval. The perioperative immunotherapy was ...
L-R: Brian Morrissey, General Manager, Michael Gately, Head of Operations and Declan Hoare, Head of Quality meet with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results